Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Gerald Hsu

Lymphoma · UCSF

View

Dr. Chadi Nabhan

Lymphoma · Ryght AI / USC

View

Dr. Mark Roschewski

Lymphoma · MSK

View

Dr. Jonathan Friedberg

Lymphoma · URMC

View

Dr. Matthew Matasar

Lymphoma · Rutgers Cancer Institute

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    MSDr. Mazyar Shadman

    Dr. Mazyar Shadman

    Hematology & Oncology · Lymphoma
    Fred Hutch Cancer Center
    mazyar

    Research

    How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor

    2025

    Via Blood

    Research

    Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy

    2025

    Via Transplantation and cellular therapy

    Research

    Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis

    2025

    Via Transplantation and cellular therapy

    Research

    CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis

    2025

    Via American journal of hematology

    Research

    CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

    2025

    Via American journal of hematology

    Research

    Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies

    2025

    Via Blood advances

    Research

    Digital pathology and image analysis of p53 biomarker in lymphomas using two algorithms: correlation with genotype and visual inspection

    2025

    Via Journal of clinical pathology

    Research

    Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials

    2025

    Via Transplantation and cellular therapy

    Research

    Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia

    2025

    Via British journal of haematology

    Research

    Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma

    2025

    Via Blood advances

    Research

    Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma

    2025

    Via British journal of haematology

    Research

    Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers

    2025

    Via Transplantation and cellular therapy

    Research

    Bispecific antibodies in action: the reality of engagement

    2025

    Via Blood

    Research

    CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting

    2025

    Via Transplantation and cellular therapy

    Research

    Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma

    2025

    Via Clinical lymphoma, myeloma & leukemia